De-risked path
Veterinary traction funds and validates entry into human oncology.
Proven technology
Combined revenue of nearly $1M since launch, with the platform in clinical use across US veterinary centers.
IP position
Both US and PCT patents, providing a solid wall of protection for years to come.
Clear direction
Defined roadmap through 510(k) clearance and acquisition readiness.